CytomX Therapeutics (CTMX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic focus and platform innovation

• Focused on developing a multimodality Probody therapeutic pipeline addressing major unmet needs in oncology.

• Pioneered conditional activation of biologics, enabling masking of antibodies in a protease-dependent manner to improve therapeutic windows.

• Maintains a strong cash position with $137 million reported at end of Q2, providing runway through 2025.

• Productive collaborations with major industry partners and over 15 active programs in the pipeline.

Clinical pipeline highlights

• Three lead clinical programs: CX-904 (T-cell engager, partnered with Amgen), CX-2051 (masked ADC, wholly owned), and CX-801 (masked interferon alpha-2b, recently entered clinic).

• CX-904 targets EGFR-positive tumors, showing promising safety and initial anti-tumor activity, especially in pancreatic cancer.

• CX-2051 targets EpCAM-positive tumors, with masking technology enabling higher tolerated doses and potential in colorectal cancer.

• CX-801 aims to localize interferon activity to tumors, reducing systemic toxicity and enabling combination with checkpoint inhibitors.

Recent data and development milestones

• CX-904 phase I data showed no cytokine release syndrome in step dosing and only one grade 3 rash among 35 patients.

• Two confirmed partial responses in late-stage pancreatic cancer; further enrollment ongoing in pancreatic, head and neck, and lung cancers.

• CX-2051 demonstrated preclinical potency and improved tolerability; dose escalation ongoing with initial phase I data expected in H1 2025.

• CX-801 began clinical dosing, with initial data anticipated by end of 2025 and plans for rapid combination studies.